Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 7,828 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Acute Disease Clear all

Conditions: Hypoxemic Respiratory Failure
Interventions: Helmet, High Flow Nasal Oxygen; Device
Lead sponsor: Baystate Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Influenza, SARS-CoV-2
Interventions: mRNA-1083; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 50 Years to 64 Years
Enrollment: 931 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 12
States / cities: Hialeah, Florida • Hollywood, Florida • Miami, Florida + 9 more

Conditions: Acute-On-Chronic Liver Failure, Ascites
Interventions: VS-01 on top of SOC, SOC (Control Group); Drug · Other
Lead sponsor: Genfit; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 13
States / cities: Sacramento, California • Washington D.C., District of Columbia • Tampa, Florida + 9 more

Conditions: Heart Failure Congestive
Interventions: Bumetanide, intranasal 4mg; Drug
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Relapsed Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Lymphoblastic Lymphoma
Interventions: Sirolimus; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Up to 30 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Coagulation
Interventions: TTP889, Placebo; Drug
Lead sponsor: vTv Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 3
States / cities: New York, New York • Spokane, Washington

Conditions: Heart Failure
Interventions: Tele-monitoring and health coaching; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 5
States / cities: Jacksonville, Florida • Mechanicsville, Virginia • Midlothian, Virginia + 2 more

Conditions: Acute Mountain Sickness
Interventions: Erythropoietin, Iron sucrose (Venofer), Sterile Sodium Chloride; Drug
Lead sponsor: University of Oregon; Other
Eligibility: 18 Years to 40 Years
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Leadville, Colorado • Eugene, Oregon

Conditions: Acute Lymphoblastic Leukemia
Interventions: Venetoclax; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Binge-Eating Disorder
Interventions: Speaking Activity, Talking Activity; Behavioral
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Acute Myocardial Infarction (AMI), Coronary Occlusion, Acute Coronary Syndrome
Interventions: Guardian System; Device
Lead sponsor: Angel Medical Systems; Industry
Eligibility: 21 Years and older
Enrollment: 1,020 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 95
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 85 more

Conditions: Multiple Organ Failure, End Stage Cardiac Failure, End Stage Chronic Obstructive Airways Disease, Chronic Kidney Disease Stage 5, Hepatic Encephalopathy, Sepsis, Dementia, Multiple Sclerosis, Parkinson's Disease, In-Hospital Cardiac Arrest, Solid Organ Cancer
Interventions: Early order of palliative care consultation; Other
Lead sponsor: Wayne State University; Other
Eligibility: 65 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2016
U.S. locations: 2
States / cities: Detroit, Michigan

Conditions: Acute ST Segment Elevation Myocardial Infarction, Acute Coronary Syndrome
Interventions: Ticagrelor, Clopidogrel; Drug
Lead sponsor: Medical Center of South Arkansas; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: El Dorado, Arkansas

Conditions: HIV Infections
Interventions: Highly Active Antiretroviral Therapy (HAART), No treatment; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Refractory Acute Myeloid Leukemia, Relapsed Acute Myelomonocytic Leukemia, Myelodysplastic Syndromes
Interventions: CPX-351; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 60 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Acute Promyelocytic Leukemia (M3), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions: cytarabine, clofarabine, filgrastim, Ex-vivo expanded cord blood progenitor cell infusion, laboratory biomarker analysis; Drug · Biological · Other
Lead sponsor: Nohla Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Venipuncture
Interventions: Lavender Aromatherapy, Jojoba Aromatherapy; Other
Lead sponsor: Children's National Research Institute; Other
Eligibility: 7 Years to 11 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Stroke
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Alameda, California

Conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Gemtuzumab Ozogamicin, Quality-of-Life Assessment, Questionnaire Administration, Talazoparib, Talazoparib Tosylate; Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Baltimore, Maryland • Buffalo, New York

Conditions: Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia
Interventions: Unmanipulated UCB, SR-1 UCB; Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 2 Years to 35 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Colitis, Ulcerative
Interventions: Delayed and extended release mesalazine; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Neck Pain, Low Back Pain
Interventions: Muscle Pattern Recognition (MPR); Device
Lead sponsor: iTech Medical, Inc.; Industry
Eligibility: 18 Years to 62 Years
Enrollment: 480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 3
States / cities: Irvine, California • Portage, Michigan • Salt Lake City, Utah

Conditions: Sickle Cell Disease
Interventions: ICA-17043; Drug
Lead sponsor: Icagen; Industry
Eligibility: 16 Years to 65 Years
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 42
States / cities: Mobile, Alabama • Little Rock, Arkansas • Davis, California + 39 more

Conditions: Acute Myeloid Leukemia
Interventions: ADCLEC.syn1 CAR T cells, Conditioning chemotherapy; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Search by objective public record fields.

A Pilot Study Comparing Oxygen Delivery Via Helmet Interface Versus High Flow Nasal Cannula

A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)

Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®

VAPorized Administration of Bumetanide for Outpatient Relief in Heart Failure

Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma

Left Ventricular Assist Device (LVAD) Specialized Centers of Clinically Orientated Research (SCCOR) Coagulation - Acute Intrinsic Pathway Antagonist (IPA)

Integrated Tele-monitoring and Patient-centric Health Coaching Strategy in Patients Hospitalized With Heart Failure

Colorado-Oregon Altitude Study

A Study of Venetoclax in Combination With Chemotherapy to Treat Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Decision Making, Daily Experiences, and Brain Activity in Young Adult Women

AngelMed for Early Recognition and Treatment of STEMI

Timing of Acute Palliative Care Consultation in Critically Ill Patients

Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis

Effectiveness of Antiretroviral Therapy During Acute HIV Infection

CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS

Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia

The Effects of Aromatherapy on the Incidence and Severity of Acute Pain

Comparative Evaluation of Stroke Triage Algorithms for Emergency Medical Dispatchers

Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia

StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies

Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis

Study to Demonstrate That Muscle Pattern Recognition (MPR) is an Effective Evaluation Tool for Musculoskeletal Neck or Back Pain

A Stratified Sickle Event Randomized Trial (ASSERT)

A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia